Through repeated and sustained occupational, industrial, and environmental sources, arsenic exposure is a world-wide health problem that affects 200 million people resulting in skin lesions, diabetes, cardiovascular disease, and cancer. Due to experimental limitations, researchers struggle to identify models that accurately reflect the consequences of long-term arsenic exposure. In this review, we will highlight the utility of in vitro studies in studying arsenic toxicity in two major target organs, skin and lungs, and propose how in vitro studies can better serve as a platform for the design of informative clinical studies.
Get full access to this article
View all access options for this article.
References
1.
Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological Profile for Arsenic (Update). Atlanta, GA: U.S. Department of Health and Human Services. Public Health Service. 2007.
2.
IARC. Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum Suppl, 1987:7; 1–440.
3.
IARC. Silica and some silicates. IARC Monogr Eval Carcinog Risk Chem Hum, 1987:42; 1–239.
4.
IARC. Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man, Vol. 2, Some Inorganic and Organometallic Compounds. Lyon; 1973, pp. 48–73.
GeorgeCM, et al.Arsenic exposure in drinking water: an unrecognized health threat in Peru. Bull World Health Organ, 2014:92; 565–572.
7.
KakizukaA, et al.Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell, 1991:66; 663–674.
8.
Lallemand-BreitenbachV, et al.Curing APL through PML/RARA degradation by As2O3. Trends Mol Med, 2012:18; 36–42.
9.
KaimingC, et al.Arsenic trioxide preferentially binds to the ring finger protein PML: understanding target selection of the drug. Metallomics, 2018:10; 1564–1569.
De JongWH, CarrawayJW, GeertsmaRE. In vivo and in vitro testing for the biological safety evaluation of biomaterials and medical devices. In: Biocompatibility and Performance of Medical Devices, 1st ed. BoutrandJ.-P. (Ed); pp. 120–158. Cambridge: Woodhead Publishing Limited, 2012.
12.
SahaJC, DikshitAK, BandyopadhyayM and SahaKC. A review of arsenic poisoning and its effects on human health. Critical Reviews in Environmental Science and Technology, 1999, 29:3; 281–313.
13.
BuchetJP, LauwerysR, RoelsH. Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. Int Arch Occup Environ Health, 1981:48; 71–79.
RatnaikeRN. Acute and chronic arsenic toxicity. Postgrad Med J, 2003:79; 391–396.
16.
ShenS, et al.Arsenic binding to proteins. Chem Rev, 2013:113; 7769–7792.
17.
SahaKC. Melanokeratosis from arsenic contaminated tubewell water. Indian J Dermatol, 1984:29; 37–46.
18.
SmithAH, LingasEO, RahmanM. Contamination of drinking-water by arsenic in Bangladesh: a public health emergency. Bull World Health Organ, 2000:78; 1093–1103.
19.
TanakaK, et al.Cysteine residues in the organic anion transporter mOAT1. Biochem J, 2004:380(Pt 1);283–287.
20.
XiaX, et al.Cys351 and Cys361 of the Na+/glucose cotransporter are important for both function and cell-surface expression. Arch Biochem Biophys, 2005:438; 63–69.
HostynekJJ, et al.Metals and the skin. Crit Rev Toxicol, 1993:23; 171–235.
23.
ValentineJL, KangHK, SpiveyG. Arsenic levels in human blood, urine, and hair in response to exposure via drinking water. Environ Res, 1979:20; 24–32.
24.
OlguinA, et al.Arsenic levels in blood, urine, hair and nails from a chronically exposed human population. Proc West Pharmacol Soc, 1983:26; 175–177.
25.
NarangAP, ChawlaLS, KhuranaSB. Levels of arsenic in Indian opium eaters. Drug Alcohol Depend, 1987:20; 149–153.
26.
TakagiY, et al.Survey of trace elements in human nails: an international comparison. Bull Environ Contam Toxicol, 1988:41; 690–695.
27.
KoonsRD, PetersCA. Axial distribution of arsenic in individual human hairs by solid sampling graphite furnace AAS. J Anal Toxicol, 1994:18; 36–40.
28.
WolfspergerM, et al.Heavy metals in human hair samples from Austria and Italy: influence of sex and smoking habits. Sci Total Environ, 1994:156; 235–242.
29.
RaieRM. Regional variation in As, Cu, Hg, and Se and interaction between them. Ecotoxicol Environ Saf, 1996:35; 248–252.
30.
DasD, et al.Arsenic in ground water in six districts of West bengal, India: the biggest arsenic calamity in the world. Part 2. Arsenic concentration in drinking water, hair, nails, urine, skin-scale and liver tissue (biopsy) of the affected people. Analyst, 1995:120; 917–924.
31.
Centers for Disease Control and Prevention. Fourth Report on Human Exposure to Environmental Chemicals. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2009.
32.
Guha MazumderDN. Chronic arsenic toxicity & human health. Indian J Med Res, 2008:128; 436–447.
33.
JaishankarM, et al.Toxicity, mechanism and health effects of some heavy metals. Interdiscip Toxicol, 2014:7; 60–72.
34.
KimC, StatesJC, CeresaBP. Chronic and acute arsenic exposure enhance EGFR expression via distinct molecular mechanisms. Toxicol In Vitro, 2020:67; 104925.
35.
CarringtonCD, MurrayC, TaoS.A quantitative assessment of inorganic arsenic in apple juice: U.S. Food and Drug Administration. 2013. www.fda.gov/media/86075/download
ChallengerF, CharltonPT. Studies on biological methylation; the fission of the mono- and di-sulphide links by moulds. J Chem Soc, 1947:169; 424–429.
38.
VahterM, MarafanteE. Reduction and binding of arsenate in marmoset monkeys. Arch Toxicol, 1985:57; 119–124.
39.
MarafanteE, VahterM, EnvallJ. The role of the methylation in the detoxication of arsenate in the rabbit. Chem Biol Interact, 1985:56; 225–238.
40.
ThomasDJ, RosenBP. Arsenic methyltransferases. In: Encyclopedia of Metalloproteins. KretsingerRH, UverskyVN, PermyakovEA (eds); pp. 140–145. New York, New York: Springer; 2013.
41.
HayakawaT, et al.A new metabolic pathway of arsenite: arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Arch Toxicol, 2005:79; 183–191.
42.
CullenWR. Chemical mechanism of arsenic biomethylation. Chem Res Toxicol, 2014:27; 457–461.
43.
NaranmanduraH, SuzukiN, SuzukiKT. Trivalent arsenicals are bound to proteins during reductive methylation. Chem Res Toxicol, 2006:19; 1010–1018.
44.
GarbinskiLD, RosenBP, ChenJ. Pathways of arsenic uptake and efflux. Environ Int, 2019:126; 585–597.
45.
StybloM, et al.Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol, 2000:74; 289–299.
46.
MassMJ, et al.Methylated trivalent arsenic species are genotoxic. Chem Res Toxicol, 2001:14; 355–361.
47.
HiranoS, et al.Difference in uptake and toxicity of trivalent and pentavalent inorganic arsenic in rat heart microvessel endothelial cells. Arch Toxicol, 2003:77; 305–312.
48.
MizumuraA, et al.Identification of arsenite-and arsenic diglutathione-binding proteins in human hepatocarcinoma cells. Toxicol Appl Pharmacol, 2010:242; 119–125.
49.
VahterM, et al.A unique metabolism of inorganic arsenic in native Andean women. Eur J Pharmacol, 1995:293; 455–462.
50.
Hopenhayn-RichC, et al.Methylation study of a population environmentally exposed to arsenic in drinking water. Environ Health Perspect, 1996:104; 620–628.
51.
ChiouHY, et al.Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Mutat Res, 1997:386; 197–207.
52.
Schlawicke EngstromK, et al.Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. Environ Health Perspect, 2007:115; 599–605.
53.
LiJ, et al.Nonsynonymous polymorphisms in the human AS3MT arsenic methylation gene: implications for arsenic toxicity. Chem Res Toxicol, 2017:30; 1481–1491.
54.
ApataM, et al.Human adaptation to arsenic in Andean populations of the Atacama Desert. Am J Phys Anthropol, 2017:163; 192–199.
55.
NaranmanduraH, et al.Comparative toxicity of arsenic metabolites in human bladder cancer EJ-1 cells. Chem Res Toxicol, 2011:24; 1586–1596.
56.
PetrickJS, et al.Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol, 2000:163; 203–207.
57.
RahmanMM, NgJC, NaiduR. Chronic exposure of arsenic via drinking water and its adverse health impacts on humans. Environ Geochem Health, 2009:31Suppl 1; 189–200.
58.
Beane FreemanLE, et al.Toenail arsenic content and cutaneous melanoma in Iowa. Am J Epidemiol, 2004:160; 679–687.
59.
KaragasMR, et al.Drinking water arsenic contamination, skin lesions, and malignancies: a systematic review of the global evidence. Curr Environ Health Rep, 2015:2; 52–68.
60.
ChenCJ, et al.Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis, 1988:8; 452–460.
61.
SmithAH, et al.Increased mortality from lung cancer and bronchiectasis in young adults after exposure to arsenic in utero and in early childhood. Environ Health Perspect, 2006:114; 1293–1296.
62.
TokarEJ, QuW, WaalkesMP. Arsenic, stem cells, and the developmental basis of adult cancer. Toxicol Sci, 2011:120Suppl 1; S192–S203.
63.
TokarEJ, et al.Carcinogenic effects of “whole-life” exposure to inorganic arsenic in CD1 mice. Toxicol Sci, 2011:119; 73–83.
64.
TokarEJ, et al.Chronic exposure of renal stem cells to inorganic arsenic induces a cancer phenotype. Chem Res Toxicol, 2013:26; 96–105.
65.
WaalkesMP, et al.Lung tumors in mice induced by “whole-life” inorganic arsenic exposure at human-relevant doses. Arch Toxicol, 2014:88; 1619–1629.
66.
PersonRJ, et al.Chronic inorganic arsenic exposure in vitro induces a cancer cell phenotype in human peripheral lung epithelial cells. Toxicol Appl Pharmacol, 2015:286; 36–43.
67.
LuoFJ, LuoZD, MaL. [A study on the relationship between drinking water with high arsenic content and incidence of malignant tumour in Heihe Village, western part of Huhehot, Inner Mongolia]. Zhonghua Liu Xing Bing Xue Za Zhi, 1995:16; 289–291.
68.
Hopenhayn-RichC, BiggsML, SmithAH. Lung and kidney cancer mortality associated with arsenic in drinking water in Cordoba, Argentina. Int J Epidemiol, 1998:27; 561–569.
69.
StatesJC, et al.Arsenic and cardiovascular disease. Toxicol Sci, 2009:107; 312–323.
70.
SimeonovaPP, et al.Arsenic exposure accelerates atherogenesis in apolipoprotein E(-/-) mice. Environ Health Perspect, 2003:111; 1744–1748.
71.
BundersonM, et al.Arsenic exposure exacerbates atherosclerotic plaque formation and increases nitrotyrosine and leukotriene biosynthesis. Toxicol Appl Pharmacol, 2004:201; 32–39.
72.
MoonK, GuallarE, Navas-AcienA. Arsenic exposure and cardiovascular disease: an updated systematic review. Curr Atheroscler Rep, 2012:14; 542–555.
73.
SidhuMS, et al.Mechanisms of action for arsenic in cardiovascular toxicity and implications for risk assessment. Toxicology, 2015:331; 78–99.
74.
KitchinKT, WallaceK. The role of protein binding of trivalent arsenicals in arsenic carcinogenesis and toxicity. J Inorg Biochem, 2008:102; 532–539.
75.
CohenSM, et al.Evaluation of the carcinogenicity of inorganic arsenic. Crit Rev Toxicol, 2013:43; 711–752.
76.
DasN, et al.Arsenic exposure through drinking water increases the risk of liver and cardiovascular diseases in the population of West Bengal, India. BMC Public Health, 2012:12; 639.
77.
TsujiJS, et al.Dose-response for assessing the cancer risk of inorganic arsenic in drinking water: the scientific basis for use of a threshold approach. Crit Rev Toxicol, 2019:49; 36–84.
78.
ZhaoL, et al.Selectivity of arsenite interaction with zinc finger proteins. Metallomics, 2012:4; 988–994.
79.
ZhouX, et al.Arsenite interacts selectively with zinc finger proteins containing C3H1 or C4 motifs. J Biol Chem, 2011:286; 22855–22863.
80.
ZhouX, et al.Differential binding of monomethylarsonous acid compared to arsenite and arsenic trioxide with zinc finger peptides and proteins. Chem Res Toxicol, 2014:27; 690–698.
81.
IARC. Arsenic and Arsenic Compounds. Lyons: IARC Press; 2012.
82.
VahterM.Methylation of inorganic arsenic in different mammalian species and population groups. Sci Prog, 1999:82 (Pt 1);69–88.
83.
StybloM, et al.Differential metabolism of inorganic arsenic in mice from genetically diverse Collaborative Cross strains. Arch Toxicol, 2019:93; 2811–2822.
84.
ShahP, et al.Arsenic induces p62 expression to form a positive feedback loop with Nrf2 in human epidermal keratinocytes: implications for preventing arsenic-induced skin cancer. Molecules, 2017:22; 194.
85.
WeiM, et al.Urinary bladder carcinogenicity of dimethylarsinic acid in male F344 rats. Carcinogenesis, 1999:20; 1873–1876.
86.
WeiM, et al.Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis, 2002:23; 1387–1397.
87.
BoffettaP, BorronC. Low-level exposure to arsenic in drinking water and risk of lung and bladder cancer: a systematic review and dose-response meta-analysis. Dose Response, 2019:17; 1559325819863634.
88.
FerreccioC, et al.Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology, 2000:11; 673–679.
89.
MostafaMG, McDonaldJC, CherryNM. Lung cancer and exposure to arsenic in rural Bangladesh. Occup Environ Med, 2008:65; 765–768.
90.
LynchHN, et al.Quantitative assessment of lung and bladder cancer risk and oral exposure to inorganic arsenic: meta-regression analyses of epidemiological data. Environ Int, 2017:106; 178–206.
91.
D'IppolitiD, et al.Arsenic in drinking water and mortality for cancer and chronic diseases in Central Italy, 1990–2010. PLoS One, 2015:10; e0138182.
92.
GuoHR, et al.Arsenic in drinking water and skin cancers: cell-type specificity (Taiwan, ROC). Cancer Causes Control, 2001:12; 909–916.
93.
ZuzoloD, et al.Arsenic: geochemical distribution and age-related health risk in Italy. Environ Res, 2020:182; 109076.
94.
MoonKA, et al.A dose-response meta-analysis of chronic arsenic exposure and incident cardiovascular disease. Int J Epidemiol, 2018:47; 1013.
95.
WangCH, et al.Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation, 2002:105; 1804–1809.
96.
MumfordJL, et al.Chronic arsenic exposure and cardiac repolarization abnormalities with QT interval prolongation in a population-based study. Environ Health Perspect, 2007:115; 690–694.
97.
HossainE, et al.Elevated levels of plasma Big endothelin-1 and its relation to hypertension and skin lesions in individuals exposed to arsenic. Toxicol Appl Pharmacol, 2012:259; 187–194.
98.
LeePC, HoIC, LeeTC. Oxidative stress mediates sodium arsenite-induced expression of heme oxygenase-1, monocyte chemoattractant protein-1, and interleukin-6 in vascular smooth muscle cells. Toxicol Sci, 2005:85; 541–550.
99.
MeekME, et al.A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol, 2003:33; 591–653.
100.
MeekME, et al.New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. J Appl Toxicol, 2014:34; 1–18.
101.
MeekME, et al.Mode of action human relevance (species concordance) framework: evolution of the Bradford Hill considerations and comparative analysis of weight of evidence. J Appl Toxicol, 2014:34; 595–606.
102.
RenQ, et al.Malignant transformation of immortalized HaCaT keratinocytes through deregulated nuclear factor kappaB signaling. Cancer Res, 2006:66; 5209–5215.
103.
RamirezR.D., et al.Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res, 2004:64; 9027–9034.
104.
GermolecDR, et al.Arsenic induces overexpression of growth factors in human keratinocytes. Toxicol Appl Pharmacol, 1996:141; 308–318.
105.
HamadehHK, et al.Coordination of altered DNA repair and damage pathways in arsenite-exposed keratinocytes. Toxicol Sci, 2002:69; 306–316.
106.
VegaL, et al.Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol Appl Pharmacol, 2001:172; 225–232.
107.
SandovalM, et al.p53 response to arsenic exposure in epithelial cells: protein kinase B/Akt involvement. Toxicol Sci, 2007:99; 126–140.
108.
BurnichonV, et al.Patterns of gene expressions induced by arsenic trioxide in cultured human fibroblasts. Toxicol Lett, 2003:143; 155–162.
109.
Al-SarrajA, ThielG. The zinc finger transcription factor Egr-1 is upregulated in arsenite-treated human keratinocytes. J Mol Med (Berl), 2004:82; 530–538.
110.
DingW, et al.Inhibition of poly(ADP-ribose) polymerase-1 by arsenite interferes with repair of oxidative DNA damage. J Biol Chem, 2009:284; 6809–6817.
111.
ZhangM, et al.AIM2 inflammasome mediates Arsenic-induced secretion of IL-1 beta and IL-18. Oncoimmunology, 2016:5; e1160182.
112.
WuX, et al.NRF2 is a potential modulator of hyperresistance to arsenic toxicity in stem-like keratinocytes. Oxid Med Cell Longev, 2017:2017; 7417694.
113.
ZhangAL, et al.Role of H3K18ac-regulated nucleotide excision repair-related genes in arsenic-induced DNA damage and repair of HaCaT cells. Hum Exp Toxicol, 2020:39; 1168–1177.
114.
MaoJ, et al.Possible differences in the mechanism of malignant transformation of HaCaT cells by arsenite and its dimethyl metabolites, particularly dimethylthioarsenics. J Trace Elem Med Biol, 2020:61; 126544.
115.
WangS, et al.Overexpression of NRF1-742 or NRF1-772 reduces arsenic-induced cytotoxicity and apoptosis in human HaCaT keratinocytes. Int J Mol Sci, 2020:21; 2014.
116.
ChenH, et al.Changes of RNA N(6)-methyladenosine in the hormesis effect induced by arsenite on human keratinocyte cells. Toxicol In Vitro, 2019:56; 84–92.
117.
DingW, HudsonLG, LiuKJ. Inorganic arsenic compounds cause oxidative damage to DNA and protein by inducing ROS and RNS generation in human keratinocytes. Mol Cell Biochem, 2005:279; 105–112.
118.
PiJ, et al.Transcription factor Nrf2 activation by inorganic arsenic in cultured keratinocytes: involvement of hydrogen peroxide. Exp Cell Res, 2003:290; 234–245.
119.
QinXJ, et al.Poly(ADP-ribose) polymerase-1 inhibition by arsenite promotes the survival of cells with unrepaired DNA lesions induced by UV exposure. Toxicol Sci, 2012:127; 120–129.
120.
HuY, JinX, SnowET. Effect of arsenic on transcription factor AP-1 and NF-kappaB DNA binding activity and related gene expression. Toxicol Lett, 2002:133; 33–45.
121.
YihLH, LeeTC. Arsenite induces p53 accumulation through an ATM-dependent pathway in human fibroblasts. Cancer Res, 2000:60; 6346–6352.
122.
OuyangW, et al.PI-3K/Akt pathway-dependent cyclin D1 expression is responsible for arsenite-induced human keratinocyte transformation. Environ Health Perspect, 2008:116; 1–6.
123.
HuangS, et al.CD44v6 expression in human skin keratinocytes as a possible mechanism for carcinogenesis associated with chronic arsenic exposure. Eur J Histochem, 2013:57; e1.
124.
GonzalezH, et al.Arsenic-exposed keratinocytes exhibit differential microRNAs expression profile; potential implication of miR-21, miR-200a and miR-141 in melanoma pathway. Clin Cancer Drugs, 2015:2; 138–147.
125.
JiangR, et al.The acquisition of cancer stem cell-like properties and neoplastic transformation of human keratinocytes induced by arsenite involves epigenetic silencing of let-7c via Ras/NF-kappaB. Toxicol Lett, 2014:227; 91–98.
126.
DodmanePR, et al.Cytotoxicity and gene expression changes induced by inorganic and organic trivalent arsenicals in human cells. Toxicology, 2013:312; 18–29.
127.
Al-EryaniL, et al.Differentially expressed mRNA targets of differentially expressed miRNAs predict changes in the TP53 axis and carcinogenesis-related pathways in human keratinocytes chronically exposed to arsenic. Toxicol Sci, 2018:162; 645–654.
128.
Al-EryaniL, et al.Cell cycle pathway dysregulation in human keratinocytes during chronic exposure to low arsenite. Toxicol Appl Pharmacol, 2017:331; 130–134.
129.
BanerjeeN, et al.Increased microRNA 21 expression contributes to arsenic induced skin lesions, skin cancers and respiratory distress in chronically exposed individuals. Toxicology, 2017:378; 10–16.
130.
ChenY, et al.Akt regulated phosphorylation of GSK-3beta/Cyclin D1, p21 and p27 contributes to cell proliferation through cell cycle progression from G1 to S/G2M Phase in low-dose arsenite exposed HaCat cells. Front Pharmacol, 2019:10; 1176.
131.
LiuZM, et al.TG-interacting factor mediates arsenic-induced malignant transformation of keratinocytes via c-Src/EGFR/AKT/FOXO3A and redox signalings. Arch Toxicol, 2015:89; 2229–2241.
132.
WuJ, et al.Overexpression of hsa-miR-186 induces chromosomal instability in arsenic-exposed human keratinocytes. Toxicol Appl Pharmacol, 2019:378; 114614.
133.
BanerjeeM, et al.Arsenite exposure displaces zinc from ZRANB2 leading to altered splicing. Chem Res Toxicol, 2020:33:1403–1417.
134.
WuJ, et al.Long-term arsenite exposure decreases autophagy by increased release of Nrf2 in transformed human keratinocytes. Sci Total Environ, 2020:734; 139425.
135.
ZhaoT, et al.N(6)-methyladenosine mediates arsenite-induced human keratinocyte transformation by suppressing p53 activation. Environ Pollut, 2020:259; 113908.
136.
XueJ, et al.CircLRP6 regulation of ZEB1 via miR-455 is involved in the epithelial-mesenchymal transition during arsenite-induced malignant transformation of human keratinocytes. Toxicol Sci, 2018:162; 450–461.
137.
LiY, et al.The repressive effect of NF-kappaB on p53 by mot-2 is involved in human keratinocyte transformation induced by low levels of arsenite. Toxicol Sci, 2010:116; 174–182.
138.
SykoraP, SnowET. Modulation of DNA polymerase beta-dependent base excision repair in cultured human cells after low dose exposure to arsenite. Toxicol Appl Pharmacol, 2008:228; 385–394.
139.
SnowET, et al.Arsenic, mode of action at biologically plausible low doses: what are the implications for low dose cancer risk?. Toxicol Appl Pharmacol, 2005:207(2Suppl);557–564.
140.
ZhangTC, SchmittMT, MumfordJL. Effects of arsenic on telomerase and telomeres in relation to cell proliferation and apoptosis in human keratinocytes and leukemia cells in vitro. Carcinogenesis, 2003:24; 1811–1817.
141.
HuangC, et al.Requirement of Erk, but not JNK, for arsenite-induced cell transformation. J Biol Chem, 1999:274; 14595–14601.
142.
IvanovVN, HeiTK. Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway. J Biol Chem, 2004:279;;22747–22758.
143.
JessenBA, et al.Keratinocyte differentiation marker suppression by arsenic: mediation by AP1 response elements and antagonism by tetradecanoylphorbol acetate. Toxicol Appl Pharmacol, 2001:174; 302–311.
144.
ReaMA, et al.Global alteration of gene expression in human keratinocytes by inorganic arsenic. Carcinogenesis, 2003:24; 747–756.
145.
LiaoWT, et al.Arsenic induces human keratinocyte apoptosis by the FAS/FAS ligand pathway, which correlates with alterations in nuclear factor-kappa B and activator protein-1 activity. J Invest Dermatol, 2004:122; 125–129.
146.
SchuligaM, ChouchaneS, SnowET. Upregulation of glutathione-related genes and enzyme activities in cultured human cells by sublethal concentrations of inorganic arsenic. Toxicol Sci, 2002:70; 183–192.
147.
PiJ, et al.Arsenic-induced malignant transformation of human keratinocytes: involvement of Nrf2. Free Radic Biol Med, 2008:45; 651–658.
148.
SunY, et al.Aberrant cytokeratin expression during arsenic-induced acquired malignant phenotype in human HaCaT keratinocytes consistent with epidermal carcinogenesis. Toxicology, 2009:262; 162–170.
149.
ZhouY, et al.Integration of microRNAome, proteomics and metabolomics to analyze arsenic-induced malignant cell transformation. Oncotarget, 2017:8; 90879–90896.
150.
AlexanderET, et al.Polyamine-stimulation of arsenic-transformed keratinocytes. Carcinogenesis, 2019:40; 1042–1051.
151.
WuX, et al.Enhanced p62-NRF2 feedback loop due to impaired autophagic flux contributes to arsenic-induced malignant transformation of human keratinocytes. Oxid Med Cell Longev, 2019:2019; 1038932.
152.
Barajas-OlmosFM, et al.Analysis of the dynamic aberrant landscape of DNA methylation and gene expression during arsenic-induced cell transformation. Gene, 2019:711; 143941.
153.
BaeDS, et al.Characterization of gene expression changes associated with MNNG, arsenic, or metal mixture treatment in human keratinocytes: application of cDNA microarray technology. Environ Health Perspect, 2002:110Suppl 6; 931–941.
154.
OlsenCE, et al.Arsenic upregulates MMP-9 and inhibits wound repair in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol, 2008:295; L293–L302.
155.
AndrewAS, et al.Arsenic activates EGFR pathway signaling in the lung. Toxicol Sci, 2009:109; 350–357.
156.
LuoF, et al.Arsenite evokes IL-6 secretion, autocrine regulation of STAT3 signaling, and miR-21 expression, processes involved in the EMT and malignant transformation of human bronchial epithelial cells. Toxicol Appl Pharmacol, 2013:273; 27–34.
157.
ChenF, et al.Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J Biol Chem, 2001:276; 11414–11419.
158.
XuY, et al.EMT and stem cell-like properties associated with HIF-2alpha are involved in arsenite-induced transformation of human bronchial epithelial cells. PLoS One, 2012:7; e37765.
159.
HeJ, et al.Chronic arsenic exposure and angiogenesis in human bronchial epithelial cells via the ROS/miR-199a-5p/HIF-1alpha/COX-2 pathway. Environ Health Perspect, 2014:122; 255–261.
160.
LuoF, et al.MicroRNA-21, up-regulated by arsenite, directs the epithelial-mesenchymal transition and enhances the invasive potential of transformed human bronchial epithelial cells by targeting PDCD4. Toxicol Lett, 2015:232; 301–309.
161.
QiY, et al.Autophagy inhibition by sustained overproduction of IL6 contributes to arsenic carcinogenesis. Cancer Res, 2014:74; 3740–3752.
162.
ChenC, et al.Protection of Nrf2 against arsenite-induced oxidative damage is regulated by the cyclic guanosine monophosphate-protein kinase G signaling pathway. Environ Toxicol, 2017:32; 2004–2020.
163.
ChenC, et al.Arsenite-induced endoplasmic reticulum-dependent apoptosis through disturbance of calcium homeostasis in HBE cell line. Environ Toxicol, 2017:32; 197–216.
164.
JaspersI, SametJM, ReedW. Arsenite exposure of cultured airway epithelial cells activates kappaB-dependent interleukin-8 gene expression in the absence of nuclear factor-kappaB nuclear translocation. J Biol Chem, 1999:274; 31025–31033.
165.
SherwoodCL, et al.Arsenic alters ATP-dependent Ca(2)+ signaling in human airway epithelial cell wound response. Toxicol Sci, 2011:121; 191–206.
166.
EfremenkoAY, et al.Evaluation of gene expression changes in human primary lung epithelial cells following 24-hr exposures to inorganic arsenic and its methylated metabolites and to arsenic trioxide. Environ Mol Mutagen, 2015:56; 477–490.
167.
LauAT, HeQY, ChiuJF. A proteome analysis of the arsenite response in cultured lung cells: evidence for in vitro oxidative stress-induced apoptosis. Biochem J, 2004:382(Pt 2);641–650.
168.
LauAT, et al.Opposed arsenite-induced signaling pathways promote cell proliferation or apoptosis in cultured lung cells. Carcinogenesis, 2004:25; 21–28.
169.
LiuY, et al.Arsenic represses airway epithelial mucin expression by affecting retinoic acid signaling pathway. Toxicol Appl Pharmacol, 2020:394; 114959.
BombergerJM, et al.Arsenic promotes ubiquitinylation and lysosomal degradation of cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels in human airway epithelial cells. J Biol Chem, 2012:287; 17130–17139.
172.
LingM, et al.Regulation of miRNA-21 by reactive oxygen species-activated ERK/NF-kappaB in arsenite-induced cell transformation. Free Radic Biol Med, 2012:52; 1508–1518.
173.
SherwoodCL, LantzRC, BoitanoS. Chronic arsenic exposure in nanomolar concentrations compromises wound response and intercellular signaling in airway epithelial cells. Toxicol Sci, 2013:132; 222–234.
174.
ChenF, et al.Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A, 2002:99; 1990–1995.
175.
ChenF, et al.Contrasting roles of NF-kappaB and JNK in arsenite-induced p53-independent expression of GADD45alpha. Oncogene, 2001:20; 3585–3589.
176.
ShenL, et al.Feedback regulations of miR-21 and MAPKs via Pdcd4 and Spry1 are involved in arsenite-induced cell malignant transformation. PLoS One, 2013:8; e57652.
177.
LiY, et al.mot-2-Mediated cross talk between nuclear factor-B and p53 is involved in arsenite-induced tumorigenesis of human embryo lung fibroblast cells. Environ Health Perspect, 2010:118; 936–942.
178.
TuW, et al.Arsenite downregulates H3K4 trimethylation and H3K9 dimethylation during transformation of human bronchial epithelial cells. J Appl Toxicol, 2018:38; 480–488.
179.
ChenC, et al.MicroRNA-155 regulates arsenite-induced malignant transformation by targeting Nrf2-mediated oxidative damage in human bronchial epithelial cells. Toxicol Lett, 2017:278; 38–47.
180.
GanapathyS, et al.Chronic low dose arsenic exposure preferentially perturbs mitotic phase of the cell cycle. Genes Cancer, 2019:10; 39–51.
181.
CuiJ, et al.M2 polarization of macrophages facilitates arsenic-induced cell transformation of lung epithelial cells. Oncotarget, 2017:8; 21398–21409.
182.
ChenQY, CostaM. Oncogenic and tumor suppressive roles of special AT-rich sequence-binding protein. J Carcinog, 2018:17; 2.
183.
WuL, et al.Autophagy mediates bronchial cell malignant transformation induced by chronic arsenic exposure via MEK/ERK1/2 pathway. Toxicol Lett, 2020:332; 155–163.
184.
SchmidlinCJ, et al.Chronic arsenic exposure enhances metastatic potential via NRF2-mediated upregulation of SOX9. Toxicol Appl Pharmacol, 2020:402; 115138.
185.
GuS, et al.N(6)-methyladenosine mediates the cellular proliferation and apoptosis via microRNAs in arsenite-transformed cells. Toxicol Lett, 2018:292; 1–11.
186.
GoodaleBC, RayackEJ, StantonBA. Arsenic alters transcriptional responses to Pseudomonas aeruginosa infection and decreases antimicrobial defense of human airway epithelial cells. Toxicol Appl Pharmacol, 2017:331; 154–163.
187.
XuW, et al.HIF-2alpha, acting via miR-191, is involved in angiogenesis and metastasis of arsenite-transformed HBE cells. Toxicol Res (Camb), 2016:5; 66–78.
188.
YangX, et al.Continuous activation of Nrf2 and its target antioxidant enzymes leads to arsenite-induced malignant transformation of human bronchial epithelial cells. Toxicol Appl Pharmacol, 2015:289; 231–239.
189.
XuY, et al.Exosomal miR-21 derived from arsenite-transformed human bronchial epithelial cells promotes cell proliferation associated with arsenite carcinogenesis. Arch Toxicol, 2015:89; 1071–1082.
190.
ZhaoY, et al.Angiogenesis, mediated by miR-21, is involved arsenite-induced carcinogenesis. Toxicol Lett, 2013:223; 35–41.
191.
XuY, et al.Involvement of HIF-2alpha-mediated inflammation in arsenite-induced transformation of human bronchial epithelial cells. Toxicol Appl Pharmacol, 2013:272; 542–550.
192.
SherwoodCL, et al.Arsenic compromises conducting airway epithelial barrier properties in primary mouse and immortalized human cell cultures. PLoS One, 2013:8; e82970.
193.
VogtBL, RossmanTG. Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts—a possible mechanism for arsenite's comutagenicity. Mutat Res, 2001:478; 159–168.
194.
WenG, et al.Neoplastic transformation of human small airway epithelial cells induced by arsenic. Mol Med, 2008:14; 2–10.
195.
CarpenterRL, et al.Arsenite induces cell transformation by reactive oxygen species, AKT, ERK1/2, and p70S6K1. Biochem Biophys Res Commun, 2011:414; 533–538.
196.
ZhongM, et al.Malignant transformation of human bronchial epithelial cells induced by arsenic through STAT3/miR-301a/SMAD4 Loop. Sci Rep, 2018:8; 13291.
197.
WangW, et al.Changes in energy metabolism and macrophage polarization: potential mechanisms of arsenic-induced lung injury. Ecotoxicol Environ Saf, 2020:204; 110948.
198.
WangL, et al.HB-EGF activates the EGFR/HIF-1alpha pathway to induce proliferation of arsenic-transformed cells and tumor growth. Front Oncol, 2020:10; 1019.
199.
VermeulenK, Van BockstaeleDR, BernemanZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif, 2003:36; 131–149.
200.
BowerJJ, et al.Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. NPJ Breast Cancer, 2017:3; 9.
201.
WangH, et al.microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1. BMC Cancer, 2019:19; 738.
202.
WuY, et al.MicroRNA-21 (Mir-21) Promotes cell growth and invasion by repressing tumor suppressor PTEN in colorectal cancer. Cell Physiol Biochem, 2017:43; 945–958.
203.
ShiC, et al.Novel evidence for an oncogenic role of microRNA-21 in colitis-associated colorectal cancer. Gut, 2016:65; 1470–1481.
204.
YagerJW, et al.Evaluation of gene expression changes in human primary uroepithelial cells following 24-hr exposures to inorganic arsenic and its methylated metabolites. Environ Mol Mutagen, 2013:54; 82–98.
205.
RuschV, et al.Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res, 1997:3; 515–522.
206.
PutnamEA, et al.Autocrine growth stimulation by transforming growth factor-alpha in human non-small cell lung cancer. Surg Oncol, 1992:1; 49–60.
207.
IshikawaN, et al.Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res, 2005:65; 9176–9184.
208.
MalmSW, AmouzouganEA, KlimeckiWT. Fetal bovine serum induces sustained, but reversible, epithelial-mesenchymal transition in the BEAS-2B cell line. Toxicol In Vitro, 2018:50; 383–390.
209.
ZhaoF, KlimeckiWT. Culture conditions profoundly impact phenotype in BEAS-2B, a human pulmonary epithelial model. J Appl Toxicol, 2015:35; 945–951.
210.
ChakrabortiD, et al.Groundwater arsenic contamination in the Ganga River Basin: a future health danger. Int J Environ Res Public Health, 2018:15:180.
211.
AhmadSA, KhanMH, HaqueM. Arsenic contamination in groundwater in Bangladesh: implications and challenges for healthcare policy. Risk Manag Healthc Policy, 2018:11; 251–261.
212.
FrostFJ, et al.Identifying US populations for the study of health effects related to drinking water arsenic. J Expo Anal Environ Epidemiol, 2003:13; 231–239.
213.
AyotteJD, et al.Estimating the high-arsenic domestic-well population in the conterminous United States. Environ Sci Technol, 2017:51; 12443–12454.
214.
PiJ, et al.Decreased serum concentrations of nitric oxide metabolites among Chinese in an endemic area of chronic arsenic poisoning in inner Mongolia. Free Radic Biol Med, 2000:28; 1137–1142.
215.
PoseyT, et al.Arsenic-induced changes in the gene expression of lung epithelial L2 cells: implications in carcinogenesis. BMC Genomics, 2008:9; 115.
216.
AposhianHV. Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu Rev Pharmacol Toxicol, 1997:37; 397–419.
217.
HealySM, et al.Enzymatic methylation of arsenic compounds. V. Arsenite methyltransferase activity in tissues of mice. Toxicol Appl Pharmacol, 1998:148; 65–70.
